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Abstract: Since the beginning of the human immunodeficiency virus (HIV) epidemic, many groups
of drugs characterized by diverse mechanisms of action have been developed, which can suppress
HIV viremia. 3-O-(3′,3′-Dimethylsuccinyl) betulinic acid, known as bevirimat (BVM), was the first
compound in the class of HIV maturation inhibitors. In the present work, phosphate and phosphonate
derivatives of 3-carboxyacylbetulinic acid were synthesized and evaluated for anti-HIV-1 activity.
In vitro studies showed that 30-diethylphosphonate analog of BVM (compound 14a) has comparable
effects to BVM (half maximal inhibitory concentrations (IC50) equal to 0.02 µM and 0.03 µM,
respectively) and is also more selective (selectivity indices: 3450 and 967, respectively). To investigate
the possible mechanism of antiviral effect of 14a, molecular docking was carried out on the C-terminal
domain (CTD) of HIV-1 capsid (CA)–spacer peptide 1 (SP1) fragment of Gag protein, designated
as CTD-SP1, which was described as a molecular target for maturation inhibitors. Compared with
interactions between BVM and the protein, an increased number of strong interactions between
ligand 14a and protein, generated by the phosphonate group, was observed.
Keywords: anti-HIV-1; bevirimat; natural products; phosphate; phosphonate; molecular docking;
molecular docking simulations
1. Introduction
Acquired immunodeficiency syndrome (AIDS) is a disease that is still rapidly spreading in
many countries and, due to its range, has been called a global epidemic. It is caused by the human
immunodeficiency virus (HIV), a member of the retrovirus family, which attacks the cells of the
immune system by destroying or impairing their functions. This gradually reduces the host’s ability to
fight infections. According to United Nations Program on HIV/AIDS, at the end of 2017, there were
36.9 million people infected with HIV around the world. Intensive research aimed at developing new
therapies and implementing prevention programs has reduced viral transmission and the mortality of
HIV-1-infected patients. Compared to the number in 2010, the number of the annual global AIDS-related
deaths in 2017, which is 940,000, was decreased by 34% [1].
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The HIV mutates quickly, resulting in the ineffectiveness of treatment and the development of
drug-resistant strains. Therefore, the search for new substances with antiviral activity is still of high
importance. Moreover, such new substances should have different mechanisms of action than currently
used therapeutics, thus allowing them to be used in a more convenient treatment regimen.
An important method of obtaining new therapeutic agents is the modification of existing
leads, that is, substances with known biological activity in terms of optimizing their properties.
Such substances include compounds derived from natural sources, like lupane-type pentacyclic
triterpene —betulin (lup-20(29)-ene-3β,28-diol), as well as its oxidation product—betulinic acid
(3β-hydroxy-20(29)-lupaene-28-oic acid).
These compounds, as well as their derivatives, have a broad spectrum of biological activity,
including anticancer, antiviral, antimalarial, antibacterial, anti-inflammatory and hepatoprotective
effects [2–4]. However, betulin derivatives inhibiting the HIV-1 replication were described for the
first time in 1994 and included betulinic acid (half maximal effective concentration (EC50) = 1.6 µM,
therapeutic index (TI) = 9.3) and dihydrobetulin (EC50 = 0.9 µM, TI = 14) [5]. Betulin, betulinic
acid and betulonic acid have weak activity against HIV-1 [6]. However, betulinic acid derivatives
represent a promising class of compounds active against the HIV virus. Mayaux et al. described
the amide derivatives of betulinic acid designated as RP 70034, RPR 103611 and a derivative of
30-hydroxybetulinic acid, designated as RP 72046, which block the HIV entry into the cell [7]. Studies of
primary amides of betulinic acid with a terminal carboxylic group of various alkyl chain lengths,
as well as products of their condensation with α, β or γ-amino acids (introduction of an additional side
chain amide group), confirmed that the most active compound is the one designated as RPR 103611
and its diastereoisomer IC9564 [8,9]. The greatest hope for a breakthrough in HIV/AIDS therapy was
raised by the 3-O-(3′,3′-dimethylsuccinyl) betulinic acid (bevirimat, BVM; Figure 1) synthesized by the
Kuo-Hsiung Lee team [10].
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In relation to HIV-1-infected H9 ly phocytes, an EC of 0.0035 µ and a TI of 20,000 were
determined for this compound [9,10]. The results of further studies have shown that this HIV-1 inhibitor
was the first antiretroviral compound defining a new class of drugs with a mechanism of action affecting
the virion maturation process and termed maturation inhibitors [11]. The process of replication of
HIV-1 ends with virion maturation, which consists of a series of cleavages of virus Gag polyprotein.
As a result of this process, a fully processed subpeptides (MA: matrix protein, CA: capsid, SP1: spacer
peptide 1, NC: nucleocapsid protein, SP2: spacer peptide 2 and P6: protein) emerge. In the last and
slowest step of maturation, HIV protease cleaves a peptide bond between CA and SP1. After that,
multiple CA peptides rearrange to create a cone-shaped core, which is critical to the formation of mature
and infectious virion [12]. This molecular target is currently used in previously approved antiretrovirals
protease inhibitors, such as nelfinavir and indinavir. However, the effectiveness of these drugs is
systematically dropping as a result of the emergence of drug-resistant and cross-resistant mutants [13].
Maturation inhibitors use the same mechanism of action, but their molecular targets are distinct.
As opposed to inhibitors which affect HIV protease, maturation inhibitors bind to its substrate (CA–SP1
peptide) and prevent the enzyme from cleaving Gag polyprotein. Accumulation of CA–SP1 peptides
with the absence of assembled CA proteins leads to loss of infectivity. Interestingly, even mutants
resistant to other drug classes remain vulnerable to BVM. BVM has been subjected to clinical testing,
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which was suspended in phase IIb in 2010, as a result of the emergence of resistance resulting from
the mutation of CA–SP1 protein found in about 55% of patients infected with HIV [14]. Nevertheless,
BVM has become a prototype of a promising group of maturation inhibitors. Many research groups
are working on the synthesis of second-generation inhibitors, also based on the structure of pentacyclic
triterpenes, which have improved activity against viruses with SP1 polymorphism [15].
In the search for new active anti-HIV substances that demonstrate high activity and selectivity
and reduced toxicity, numerous modifications of the betulin and betulinic acid structure at C3, C28 as
well as C30 were performed [16–19]. However, compounds in which a phosphonate group is directly
linked to the triterpene system have not been described so far.
Compounds containing a phosphorus atom play an increasingly important role in medical
chemistry. For example, phosphonates are compounds commonly found in living organisms.
They constitute a group of compounds with antiviral and antibiotic activity. Important examples of such
antibiotics with broad application in medicine include fosfomycin (a strong effect on Gram-negative
bacteria and Gram-positive bacteria), fosmidomycin (antimalarial activity), rhizocticin (antifungal
activity) and plumbemycin (antimicrobial activity) [20–23]. Important antivirals include cidofovir
(active against herpes simplex virus (HSV)-1, HSV-2 and Epstein–Barr virus), adefovir and pradefovir
(active against hepatitis B virus (HBV)), tenofovir (active against HIV-1, HIV-2 and HBV) and foscarnet
(active against herpes viruses and HIV) [24–26]. The US patent 2013/0225532 A1 discloses phosphonate
compounds active against wild strains of human and bird influenza H1N1, H5N1 and H3N2 viruses
resistant to oseltamivir [27]. Moreover, phosphonate derivatives of triterpenes with antiviral activity
have been described in several patents. However, the phosphonate group is not linked directly to the
triterpene system but is located in the long substituent chain at C3 or C28 positions [28–30].
Phosphonates have a P–C bond which, in comparison to the P–O–C bond, has greater stability.
As a result, phosphates with a P–O–C bond can be part of a pharmacophore or prodrug element that is
cleaved before reaching a molecular target [31]. An example of a phosphate prodrug is fosamprenavir,
designed to improve the pharmacokinetics of an oral antiviral drug—amprenavir [32]. To solve the
problems of administration and the low bioavailability of triterpenoids, phosphate prodrugs can also be
used. For example, phosphate prodrugs of betulin are described in the US Patent 2003/6569842B2 [33].
The subject of this work is the synthesis and evaluation of anti-HIV activity of new compounds,
based on the structure of 3-O-(3′,3′-dimethylsuccinyl) betulinic acid (BVM), modified by introducing
the phosphonate or phosphate substituent directly to the triterpene system. For BVM and for the most
active in vitro compounds, molecular docking to the active sites of CA–SP1 protein was conducted.
The ligand–target interactions are dependent on the poses (conformation and the relative orientation)
of both the host and guest molecule; therefore, molecular dynamics simulations (MDS) were also
performed to assess system stability.
2. Results and Discussion
2.1. Chemistry
Considering the literature information presented above, it seemed interesting to connect,
in one molecule, a residue of a compound with known and reported activity against HIV-1,
i.e., 3-carboxyacylbetulinic acid with a phosphate or phosphonate group. This paper is an attempt to
answer the question of how this modification of the BVM structure affects the activity of the compounds
obtained. For this purpose, three series of phosphorus derivatives were synthesized. These are
compounds with the phosphate group in the C30 position (3, 6, 9 and 12a–c), with the phosphonate
group in the C29 position (4, 7, 10 and 13a–c) and also with the phosphonate group in the C30 position
(5, 8, 11 and 14a–c) (Scheme 1).
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Scheme 1. Synthesis of phosphorus derivatives of 3-carboxyacylbetulinic acid 12a–c, 13a–c and 14a–c.
The starting substance used in the work was 3,28-diacetylbetulin. This compound was converted
into the 30-phosphate 1 and 30-phosphonate derivative 2 according to previously described
procedures [34,35]. Betulin phosphate 1 was then subjected to an alkaline hydrolysis reaction to
give 30-diethoxyphosphoryloxybetulin 3 with a yield of 85% [34].
As described, the electron-withdrawing effect of the phosphonate moiety in compound 2 increases
the acidity ofα protons and, under basic conditions, leads to allyl-vinyl isomerization [35]. To hydrolyze
the acetyl groups at both the C28 and C3 positions, the reaction should be carried out at room
temperature for 6 h. Under such conditions, a mixture of products that are difficult to separate is
formed. As previously observed, the hydrolysis reaction of compound 2 carried out in an ethanolic
KOH solution at the boiling point proceeds almost entirely with allyl-vinyl isomerization and leads to
29-phosphonobetulin 4 (61%) [35]. Compounds 3 and 4 containing hydroxyl groups at the positions of
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C3 and C28 were further transformed in the same manner (Scheme 1). First, in the reaction with the
Jones reagent, the hydroxyl groups at the C3 and C28 positions were oxidized to the carbonyl group
and the carboxyl group, respectively. In this way, 30-phosphate 6 and 29-phosphonate 7 derivatives
of betulonic acid (yields of 35% and 31%, respectively) were obtained. The reduction carried out
in the next step using sodium borohydride led to the formation of the corresponding betulinic acid
derivatives 9 and 10 with yields of 61% and 50%, respectively.
To synthesize the 30-phosphonate derivative of betulinic acid 11, it was necessary to use a
different reaction scheme. For this purpose, compound 2 was hydrolyzed under milder conditions
(room temperature) and for less time. Such a change in the procedure made it possible to obtain
30-phosphonate of 3-acetylbetulin 5 at a yield of 61% [36]. Then, the hydroxy group at the C28 position
was oxidized with the Jones reagent, which resulted in formation of 3-acetyl-30-phosphonobetulinic
acid 8 at a 63% yield. This compound was hydrolyzed at the C3 position to give a 30-phosphonate
derivative of betulinic acid 11 at a yield of 66%.
Table 1 shows the different conditions for the alkaline hydrolysis reaction for the formation of
phosphonate derivatives 4, 5 and 11.
Table 1. A comparison of the alkaline hydrolysis reaction conditions leading to the formation of
phosphonate compounds 4, 5 and 11.
Compound Solvent Temperature (Temp.) [◦C] Time [h] Yield [%]
4 KOH in CH3CH2OH Reflux 2 61
5 NaOH in CH3OH/H2O/THF Room temp. 0.5 61
11 NaOH in CH3OH/H2O/THF Room temp. 24 66
The last step in the synthesis of the target compounds was acylation of the phosphorus derivatives
of betulinic acid 9–11 with 2,2- and 3,3-dimethyl glutaric and dimethylsuccinic anhydrides. In the
literature, several methods of performing this reaction are described. In our work, we adopted a quick
and easy method of using a microwave reactor. The reactions were carried out at 130 ◦C–160 ◦C to give
the corresponding 3-carboxyacyl derivatives 12a–c, 13a–c and 14a–c with yields in the range of 20–41%.
2.2. Cytotoxicity and Antiretroviral Activity
The anti-HIV activity of synthesized compounds 9–14 were evaluated against HIV-1 in CEM-T4
cell line. The first stage in the study of biological activity was the assessment of cytotoxicity of
synthesized compounds using the MTT assay (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide applied as a reductive coloring agent). The results were expressed as a compound concentration
causing 50% cell death (CC50). Evaluation of anti-HIV activity consisted of measurements of p24
antigen using the Genscreen ULTRA HIV Ag-Ab Kit. The anti-HIV activity data were expressed as a
concentration of tested compound showing 50% inhibition of replication (IC50). We included betulin
and betulinic acid in our studies in order to broaden the structure-activity study. BVM, the first HIV-1
maturation inhibitor, was applied as a reference compound. The bioassay results are shown in Table 2.
Table 2. Anti-HIV-1 replication activities in human immunodeficiency virus (HIV)-infected CEM-T4
cell line.
Compound CC50 (µM) IC50 (µM) TI
bevirimat
betulinic acid
betulin
29 ± 2.43 0.03 ± 0.009 967
5 ± 2.44 NO -
46±3.01 NO -
9
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obtained. Compounds 12c, 13c and 14c, all containing the 4′,4′-dimethylglutaric group, were 
characterized by the weakest anti-HIV activity and the IC50 values determined for them were within 
the range of 1 to over 10 μM. According to the literature reports, 3′,3′-dimethylglutarylbetulinic acid 
was characterized by lower activity than BVM (EC50 = 0.0023 μM and 0.00035 μM, respectively) [10]. 
However, triterpene derivatives with 3′,3′-dimethylglutaric moiety such as betulin and 28-
aminoanalogs of betulin as well as 28-alkylaminobetulin have demonstrated a very high ability to 
inhibit HIV replication [37,38]. Sun at al. described 3,28-di(dimethylglutaryl)betulin, which 
demonstrated strong activity (EC50 = 0.00066 μM) and high selectivity (TI = 21515) [37]. Phosphorus 
derivatives 12b, 13b and 14b with 3′,3′-dimethylglutaric substituent showed significantly lower 
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The succinic derivatives 13a and 14a have the same cytotoxicity (CC50 value of >68 μM, Figure 
2) and at the same time show very different activities against HIV-1. The IC50 value for the allylic 
derivative 14a is 100-fold higher than for the vinylic derivative 13a (IC50 value equal to 0.02 ± 0.01 and 
2 ± 0.72 μM, respectively). 
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In the study, betulin and betulinic acid did not demonstrate the ability to inhibit HIV replication
in the range of concentrations tested. Introduction of a diethylphosphonate substituent in the C29
(compound 10) or C30 (compound 11) position of the isopropenyl moiety resulted in an increase in
activity as compared to the starting betulinic acid. However, the activity of derivatives 10 and 11 is
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low, with IC50 values above 10 µM. The presence of the diethylphosphate group did not improve the
activity of compound 9.
As can be seen in Table 2, the presence of a phosphorus atom in the tested betulinic acid derivatives
leads to a decrease in the cytotoxic effect relative to the CEM-T4 cell line compared to betulinic
acid. This effect is more pronounced for phosphonate derivatives (10 and 11) than for the phosphate
one (9). In addition, the location of the double bond in betulinic acid phosphonate derivatives has
little effect on cytotoxicity measured as a cytotoxic concentration CC50, that is, as the compound’s
concentration required for the reduction of cell viability by 50%. For example, the values for vinyl
isomer 10 is 80 ± 1.3 µM and for allyl isomer 11 is higher than 42 µM. Charts of changes in cytotoxicity
of all synthesized compounds in the tested concentration range are given in Supplementary Materials
(Figures S1–S13).
When the hydroxyl substituent at the C3 position of the phosphobetulinic acid scaffold was changed
to the carboxyacyloxy group, there was an improvement in the activity of the derivatives obtained.
Compounds 12c, 13c and 14c, all containing the 4′,4′-dimethylglutaric group, were characterized
by the weakest anti-HIV activity and the IC50 values determined for them were within the range
of 1 to over 10 µM. According to the literature reports, 3′,3′-dimethylglutarylbetulinic acid was
characterized by lower activity than BVM (EC50 = 0.0023 µM and 0.00035 µM, respectively) [10].
However, triterpene derivatives with 3′,3′-dimethylglutaric moiety such as betulin and 28-aminoanalogs
of betulin as well as 28-alkylaminobetulin have demonstrated a very high ability to inhibit HIV
replication [37,38]. Sun at al. described 3,28-di(dimethylglutaryl)betulin, which demonstrated strong
activity (EC50 = 0.00066 µM) and high selectivity (TI = 21515) [37]. Phosphorus derivatives 12b, 13b
and 14b with 3′,3′-dimethylglutaric substituent showed significantly lower activity (values of IC50
equal to 0.6 ± 0.04, 8.8 ± 1.70 and 0.9 ± 0.12 µM, respectively) (Table 2).
The highest activity in the group of compounds that were tested was found for
3-(3′,3′-dimethylsuccinyl) betulinic acid derivatives 12a, 13a and 14a, for which the IC50 values
are below 2 µM (Table 2).
The succinic derivatives 13a and 14a have the same cytotoxicity (CC50 value of >68 µM, Figure 2)
and at the same time show very different activities against HIV-1. The IC50 value for the allylic
derivative 14a is 100-fold higher than for the vinylic derivative 13a (IC50 value equal to 0.02 ± 0.01 and
2 ± 0.72 µM, respectively).
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Compound 14a inhibits viral replication at a level comparable to the reference—BVM (values of 
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Figure 2. Cytotoxicity (CC50) of 3-carboxyacylbetulinic aci s divi ed into groups of corresponding
phosphorus derivatives (30-phosphate: 12a–c; 29-phosphonate: 13a–c; 30-phosphonate: 14a–c) and
BVM used as a reference. (* the mean measuring error of absorbance at the highest concentration.)
Compound 14a inhibits viral replication at a level comparable to the reference—BVM (values of
IC50 equal to 0.02 ± 0.01 and 0.03 ± 0.009 µM, respectively). It should be noted that the advantage of
the synthesized derivative 14a is that it has lower cytotoxicity to the cells tested compared to BVM
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(Figure 3). The selectivity index for this substance is 3450 and for the reference BVM is equal to 967
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2.2. Molecular Docking Study 
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In the case of derivatives with 3′,3′-dimethylsuccinic and 3′,3′-dimethylglutaric substituents in the
C3 position, their activities increase in the order: 29-phosphonate < 30-phosphate < 30-phosphonate.
After analyzing the results, it can be concluded that the introduction of a diethylphosphonate group
in the C30 position of the 3-carboxyacylbetulinic acids has increased the ability of the obtained products
(14a–c) to inhibit HIV-1 replication. The corresponding derivatives containing the diethylphosphonate
group in the vinyl position (C29), 13a–c, have the lowest activity, regardless of the substitution in the
C3 position. Similarly, in the case of 30-phosphate derivatives 12a–c, the presence of an additional
oxygen atom does not improve the anti-HIV properties of the compounds obtained (Figure 4).
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BVM used as a reference. (* the mean measuring error of absorbance at the highest concentration.)
Moreover, the higher activity of 3′,3′-dimethylsuccinic (12a and 14a) and 3′,3′-dimethylglutaric
(12b and 14b) derivatives as compared to that of 4’,4’-dimethylglutaric (12c and 14c) confirms that an
important structural element which determines activity is the presence of two methyl groups on the
third carbon atom in the C3 ester substituent.
2.3. Molecular Docking Study
In the group of triterpenoids acting against HIV-1, compounds acting by blocking the virus entry
into cells, inhibition of reverse transcriptase and protease, as well as inhibition of virus maturation
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have been described [4]. Additionally, studies of anti-HIV betulinic acid derivatives showed different
mechanisms of their action [39]. Depending on the structure of the substituents at C3 and C28,
these compounds act at various stages in the virus life cycle. Derivatives, in which the carboxyl group
at the C17 position has been converted to an amide function with various substituents, inhibit the
entry of the virus into the cell. Replacement of the hydroxyl group at the C3 position with the amide
substituent reduces the activity, whereas the introduction of the ester group gives compounds with high
activity and a different mechanism of action, the so-called maturation inhibitors [40]. The derivative
14a, the most active in vitro synthesized compounds, is a 30-diethylphosphonate analog of BVM, so it
can be expected to interact with the same molecular target.
Molecular docking techniques were applied to investigate binding mechanisms for the series of
phosphorus derivatives of 3-carboxyacylbetulinic acid (12a–c, 13a–c, 14a–c) and BVM was selected
as a reference compound. The tested compounds can exist as two chemical species: carboxylic acids
or carboxylate salts depending on the pH of the aqueous solution. Calculations performed with the
ACD/Percepta software [41] for BVM and 14a show that in both cases the content of the carboxylate
states at physiological pH is 100%. Therefore, for docking studies, hydrogens present in the carboxylic
groups were removed to mimic the protonation states of these groups.
NMR and cryo-EM data show that in CA–SP1 tubes assembled in vitro, which represent the
features of an intermediate assembly state during maturation, the SP1 peptide exists in a dynamic
helix–coil equilibrium, and that the addition of the maturation inhibitor, i.e., BVM, causes stabilization
of the helical form of SP1. Dynamics of CA and SP1 are critical for orderly HIV-1 maturation and the
small molecule can inhibit maturation by perturbing molecular motions [42].
Based on atomic coordinates of the C-terminal domain (CTD) of CA and SP1, designated as
CTD-SP1 fragment of HIV-1 Gag and deposited in the Protein Data Bank (PBD ID 5I4T), one active
site cavity was predicted [43]. This cavity was located inside the pore formed by the six-helix SP1
bundle (Figure 5). As a result of docking the computational models of betulin derivatives to the
active sites of CTD-SP1, 21 possible ligand–protein complexes were obtained. \All docked compounds
bind in the pore region but bind to several different residues through different types of interactions.
The superpositions of studied compounds inside CTD-SP1 (poses) were scored according to their
binding energies (Table 3).
Table 3. Binding affinities of 3-carboxyacylbetulinic acids (12a–c, 13a–c, 14a–c).
Compound 12a 12b 12c 13a 13b 13c 14a 14b 14c BVM
Binding energy
∆G [kcal/mol] −6.13 −5.61 −7.14 −6.73 −7.55 −8.20 −7.30 −6.89 −6.74 −8.12
Docking solutions with the lowest total score correspond to the highest binding affinities and present the most
probable systems in vivo.
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According to the literature data on interaction of BVM with CA CTD-SP1 protein [42], carboxylate
moiety of the ligand has ionic interactions with common residue Lys227 in chain I and Lys227 residue
in chain L (Figure 6). In addition, numerous hydrophobic interactions, including carbon–hydrogen
bonds and carbon–carbon bonds, influence the increased stability of the complex (Table 4).
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Figure 6. Predicted binding model of BVM with the HIV-1 CA CTD-SP1 protein.
The analyses of the complex of 14a, the most in vitro potent compound, included calculations,
distance measurements, and pose geometries that determined salt bridge interactions of the ligand
pose with Lys227 in chain I and Lys158 residues of chains G and K. Moreover, the phosphonate group
forming additional hydrogen–bond interactions of the ligand pose with Lys227 (chain J) and Lys158
(chain L) (Figure 7).
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Numerous hydrophobic interactions increase the stability of the complex (Table 4).
The analysis of the docking results presented in Table 3 shows that some of the tested compounds
(e.g., compounds 13b and 13c) show lower binding energy values compared to compound 14a. However,
detailed analysis of binding modes of 13b determined hydrogen bonds, formed by carboxylate groups
without involving a phosphonate substituent. The analysis of the complex of 13c determined salt bridge
interactions of the carboxylate groups of the ligand pose with Lys227 in chains I and J, and with Lys158
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in chain G. It is worth mentioning that, the phosphonate group formed only one, hydrogen–bond
interaction of the ligand pose with Lys158 (chain L) (Figure 8).
Table 4. Interactions between BVM, 14a, and HIV-1 CA CTD-SP1 protein.
Protein Ligand Interaction
Name Chain:Residue Name Residue Type Distance [Å]
CTD-SP1 (5I4T)
I:Lys227 BVM carboxylate salt bridge 1.90
J:Lys227 carboxylate attractive charge 3.67
I:Pro224 C-21 of betulin carbon–hydrogen bond 2.90
J:Lys227 carboxylate alkyl–alkyl 2.11
L:Gly223 carboxylate alkyl–alkyl 2.30
G:Lys158 C-21 of betulin alkyl–alkyl 4.69
L:Pro224 C-21 of betulin alkyl–alkyl 5.41
L:Lys158 C-25 of betulin alkyl–alkyl 5.28
K:Lys158 C-29 of betulin alkyl–alkyl 3.67
K:Lys158 C-30 of betulin alkyl–alkyl 3.89
G:Lys158 C-21 of betulin alkyl–alkyl 4.55
J:Lys158 C-5′ of BVM alkyl–alkyl 3.71
J:Lys158 C-6′ of BVM alkyl–alkyl 4.76
I:Lys227 14a carboxylate salt bridge 1.99
G:Lys158 carboxylate carbon–hydrogen bond 2.98
K:Lys158 carboxylate carbon–hydrogen bond 5.18
J:Lys227 phosphonate conventional hydrogen bond 2.23
L:Lys158 phosphonate conventional hydrogen bond 1.97
J:Lys227 ethyl carbon–hydrogen bond 2.40
L:Lys158 phosphonate carbon–hydrogen bond 2.19
J:Gly222 ethyl carbon–hydrogen bond 3.59
I:Lys158 C-25 of betulin alkyl–alkyl 5.23
K:Lys158 C-24 of betulin alkyl–alkyl 4.94
I:Lys158 C-7 of betulin alkyl–alkyl 4.38
H:Lys158 ethyl alkyl–alkyl 5.23
J:Pro224 ethyl alkyl–alkyl 4.08
H:Lys158 ethyl alkyl–alkyl 3.69Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 12 of 21 
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The obtained results indicate that the introduction of the diethylphosphonate group into the C30
position of betulin system causes increased stability of the ligand–receptor complex by increasing the
number of strong interactions between the ligand and the HIV-1 protein.
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2.4. Molecular Dynamics Simulations
The molecular dynamic study can provide valuable knowledge about the ligand–target stability
and mechanism of the host binding in the active site as well. The liganded states (holo) of the HIV-1
CA CTD-SP1 protein with BVM and the most potent derivative 14a were used as the initial structures
in the MDS. Due to time and computational resource restrains, docking-based MDS of BVM and 14a
molecules were performed with the flexible ligand and the rigid target protocol implemented in Sybyl-X
2.2.1 package. On the other hand, the simulations of the internal motions in a large biomolecular
system (protein) were conducted using reduced molecular dynamics (RedMD) strategy, where each
amino acid or nucleotide is represented by a single spherical particle (“bead”) centered on an alpha
carbon (Cα) or phosphorous (P) atom with mass corresponding to the total mass of a specified amino
acid or nucleotide, respectively [44–46]. RedMD simulations were carried out in the NVT ensemble
using the Berendsen algorithm for the temperature control. Initially, the atom velocities were assigned
at 293 K, but then, the system was heated and the conformational investigation was performed at 300 K.
The overall length of the RedMD simulations was set to 20 ns. The relatively constant fluctuations of
the protein kinetic/potential energy are illustrated in Figure 9A,B.
Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 12 of 21 
 
 
Figure 8. (A) Interactions between 13b and HIV-1 CA CTD-SP1 protein; (B) interactions between 13c 
and HIV-1 CA CTD-SP1 protein. 
The obtained results indicate that the introduction of the diethylphosphonate group into the C30 
position of betulin system causes increased stability of the ligand–receptor complex by increasing the 
number of strong interactions between the ligand and the HIV-1 protein. 
2.3. Molecular Dynamics Simulations  
The molecular dynamic study can provide valuable knowledge about the ligand–target stability 
and mechanism of the host binding in the active site as well. The lig nded states (holo) of the HIV-1 
CA CTD-SP1 protein with BVM a d the most potent derivative 14a were used as the initial structures 
in the MDS. Due to time and computational resource restr ins, docking-based MDS of BVM and 14a 
molecules were performed with the flexible ligand and the rigid target protocol implemented in 
Sybyl-X 2.2.1 package. On t e other hand, the simulations of the internal motions in a large 
biomole ular system (protein) were conducted using reduced molecular dynamics (RedMD) 
trategy, wh re each ami o acid or nucl otid  is represented by a singl  spherical particle (“bead”) 
centered on an alpha carbon (Cα) or phosphorous (P) atom with mass corr spondi g to the total mass 
of a specified amino acid or nucleotide, respectively [44–46]. RedMD simulations were carrie  out in 
the NVT ensemble u ing th  Berendsen algorithm for the temp ratur  control. Initially, the atom 
velocities w re assigned at 293 K, but then, the system was heated and the conformational 
investigation was performed at 300 K. The overall length of the RedMD simulations was s t to 2  ns. 
 relatively constant fluctuations of the protein kinetic/potential energy are illustrated in Figure 
9A,B. 
 
Figure 9. Kinetic (A) and potential (B) energy variations in the reduced molecular dynamics (RedMD) 
simulations of HIV-1 CA CTD-SP1 protein. 
Figure 9. Kinetic ( ) and potential (B) energy variations in the reduced olecular dyna ics (Red )
si ulations of IV-1 CA CTD-SP1 protein.
Moreover, the potential stability of the HIV-1 protein model can be confirmed by “pretty” small
variations of the root-mean-square deviation (RMSD) parameter, as shown in Figure 10.
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The set of conformers for BVM as a reference compound and the most active 14a molecule was
generated using the NVT ensemble at a temperature of 300 K. Variations of the potential/kinetic
energies as well as the temperature during the 20 ns trajectory for 14a and the reference BMV molecule
are presented in Figure 11A,B, respectively.
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Figure 12. Variations of RMSD values in MDS of molecule 14a and BVM.
Interestingly, the reference BVM compound is characterized by lower values of RMSD parameters
compared to the potent molecule 14a at the initial steps of the MDS. Obviously, the side chains of
compound 14a have direct impact on the whole molecular flexibility, especially at the beginning of MDS.
The comparable RMSD values are reached at the final step of the MDS, which confirms the relative
stability of the ligand–protein systems. In Figure 13, the initially docked-based three-dimensional (3D)
structure is compared with the averaged spatial geometry of molecule 14a produced during the MDS.
It seems that the docking protocol generated fairly stable conformation of the most active molecule
14a in the analyzed series of compounds.
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3. Materials and Method
3.1. Biological Activity
3.1.1. Cytotoxicity
F r the determination of compounds cytotoxicity, CEM-T4 cells were obtained from the NIH
AIDS Reagent Program (NIH, US) and were cultured in RPMI supplemented with 10% FCS (Biochrom)
and an ibiotics at 37 ◦C in 5% CO2 on 96-well culture plates. The experiments were carried out in
media containing tested compounds in concentrations of 4.25, 8.5, 17, 34 and 68 µM. Cultures in a
neat medium (RPMI, 10% FCS) were used as a control. Viability of cells was determined after 7 days
using the MTT assay [47] in which 10 µL of MTT solution (5 mg/mL) was added to each culture
plate well, and cultures were incubated for 3 h at a temperature of 37 ◦C. After the centrifugation,
the supernatant was removed, and DMSO was added for lysis of the cells and to dissolve crystals of
formazan. Color intensity was measured with a plate reader at 560 nm. Cell viability was determined
by the Equation (1):
Viability (%) = (OD of samples enriched in test drugs/OD of control samples) × 100 (1)
where OD means optical density.
Based on the calculations, a graph was created regarding the relationship between the concentration
of the compound and the viability from which CC50 was established.
3.1.2. Anti-HIV Activity
CEM-T4 cells were preincubated (culture plates with 96 flat bottom wells) for 24 h under
standard conditions (37 ◦C, 5% CO2) and in a standard medium (RPMI, FCS 10%) enriched with
tested compounds in the concentration range from 0.02 µM to 10 µM. In each well, 20,000 cells were
suspended in the solution of a tested compound (200 µL). For each concentration, cultures were run
in triplicate. A wild-type HIV-1 was isolated from the HIV-positive patient in the Laboratory of
Virology of the National Medicines Institute (Warsaw, Poland) and was used as a reference. A culture
of CEM-T4 lines in a standard neat medium (RPMU, FCS 10%) was used to produce viruses. After 24 h
of incubation in a medium enriched with a tested compound, cells were inoculated with a known
amount of HIV, and after 7 days, HIV replication was evaluated through the measurement of secreted
viral protein p24 carried out with the enzyme-linked immunosorbent assay (ELISA) technique [48].
For each tested compound and for each concentration, the measurements of p24 antigen were done
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in triplicate using the Genscreen ULTRA HIV Ag-Ab Kit (Biorad, Warszawa, Poland) and following
manufacturer’s instructions. The absorbance of the sample was determined as an OD measured at
650 nm. HIV replication capacity was calculated using the Equation (2):
Virus replication (%) = (OD of drug-enriched samples/OD of control samples) × 100 (2)
The results were presented by a graph showing the ratio of HIV replication to the concentration of
the tested preparation. The concentration of tested compound showing 50% inhibition of replication
(IC50) was read from the graph.
3.2. Synthesis
All solvents used in reactions were dried and purified according to standard procedures.
Melting points of obtained compounds were measured in open capillary tubes on an Electrothermal
melting point apparatus without correction.
1H NMR (600 MHz), 13C NMR (150 MHz) and 31P NMR (243 MHz) spectra were recorded on a
Bruker AVANCE III HD 600 spectrometer (Bruker, Billerica, MA, USA) in deuterated CDCl3. Chemical
shifts (δ) values were reported in parts per million (ppm) relative to the external standards. Multiplicity
was designated as singlet (s), doublet (d) and multiplet (m).
Infrared spectra (pellets, KBr, Merck, Darmstadt, Germany) were obtained using an IRAffinity-1
FTIR spectrometer (Shimadzu, Kyoto, Japan) and the measurement was recorded in the range of
4000–1000 cm–1 at 295 K. High-resolution mass spectra have been measured with Bruker Impact
II (Bruker, Billerica, MA, USA). Calculation of the theoretical molecular mass for compounds was
performed using “The Exact Mass Calculator, Single Isotope Version” (http://www.sisweb.com/referenc/
tools/exactmass.htm).
The progress of reaction was monitored by thin-layer chromatography (TLC) (silica gel 60 254F
plates, Merck, Darmstadt, Germany) and developed in a mixture of chloroform or dichloromethane
and ethanol (15:1, v/v). The spots were visualized by spraying them with a solution of 5% sulfuric
acid and heating to 100 ◦C. The compounds were purified by column chromatography (silica gel 60,
particle size < 63 µm, Merck) in the solvent system indicated.
Acylation reactions were performed in a microwave reactor (Discover SP-D, CEM Corporation,
Matthews, NC, USA).
Synthesis of compounds 1–5 were performed as was previously described. The melting point and 1H,
13C, 31P NMR spectral data for these compounds were consistent with the literature information [34–37].
BVM [3-O-(3′,3′-dimethylsuccinyl) betulinic acid], used in the study as a reference, was obtained
from betulin, which was oxidized and the obtained betulonic acid was first reduced and then
acylated with dimethylsuccinyl anhydride. The synthesis used the procedures described below
for phosphorus derivatives. The final product was obtained at a yield of 70%. The melting point
and spectroscopic characteristics of the compound were consistent with the literature data [10].
Characteristics and descriptions of spectroscopic data for newly synthesized compounds are included
in Supplementary Materials.
3.2.1. Synthesis of 3-Acetyl-30-Diethoxyphosphorylbetulin 5
The compound 2 (0.66 g, 1 mmol) was added to 50 mL of a 0.2 M solution of sodium hydroxide in
a mixture of methanol, tetrahydrofuran and water (1:2:1, v/v), and stirred at room temperature for 0.5 h.
When the reaction was completed, 30 mL of dichloromethane was added, and next, the mixture was
washed with a 10% solution of hydrochloric acid and then with water. The organic layer was dried with
anhydrous sodium sulphate and evaporated. Purification of the residue by column chromatography
(SiO2; chloroform/ethanol ratio: 15:1, v/v) gave product 5.
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3.2.2. General Procedures for Oxidation with the Jones Reagent
A cold solution of the Jones reagent (4 mL) was added in drops to a cooled solution of 1 mmol of
compound 3 or 4 in 14 mL of acetone, keeping the mixture temperature at about 0 ◦C. Stirring was
continued for 1.5 h at room temperature. Then, the mixture was placed in a water bath at 10 ◦C, 3 mL of
ethanol was gradually added, and stirring was continued for 30 min. After that, the mixture was poured
into 15 mL of water with crushed ice. The suspension formed was extracted with dichloromethane.
The extracts were dried with anhydrous sodium sulphate and, after concentrating, were purified by
column chromatography (SiO2; dichloromethane/ethanol ratio: 15:1, v/v) to obtain compounds 6 and 7.
Oxidation of compound 5 was carried out in the same way using 2 mL of the Jones reagent.
3.2.3. General Procedures for the Sodium Borohydride Reduction (Synthesis of Compounds 9 and 10)
To a suspension of 0.12 g (about 0.2 mmol) of compound 6 or 7 in 8 mL of tetrahydrofuran, 0.03 g
(0.72 mmol) of sodium tetrahydroborate (NaBH4) was added and stirred at room temperature for 2 h.
The reaction mixture was diluted with 15 mL of water and extracted with dichloromethane. Then,
the extracts were dried over anhydrous sodium sulfate and concentrated to dryness in a vacuum
evaporator. The residue was purified by column chromatography (SiO2; dichloromethane/ethanol
ratio: 15:1, v/v) to give the corresponding product (9 or 10).
3.2.4. Synthesis of 30-Diethoxyphosphorylbetulinic Acid 11
Compound 8 (1 mmol) was added to 60 mL of a 0.2 M solution of sodium hydroxide in a mixture of
methanol, tetrahydrofuran and water (1:2:1, v/v/v), and stirred at room temperature for 24 h. When the
reaction was completed, the volatile constituents were evaporated at a reduced pressure, and 30 mL of
dichloromethane was added to the evaporation residue, which was washed with a 10% solution of
hydrochloric acid and then with water. The organic layer was dried with anhydrous sodium sulphate.
Upon purifying, the crude product by column chromatography (SiO2; chloroform/ethanol ratio: 15:1,
v/v), compound 11 was obtained.
3.2.5. General Method of Synthesis 3-Carboxyacyl Derivatives 12a–c, 13a–c and 14a–c
To the solution of 1 mmol of appropriate acid 9, 10 or 11 in 2 mL pyridine,
N,N-dimethylaminopyridine (DMAP; 1.5 mmol, 0.19 mg) and 5 mmol of appropriate acid anhydride
(2,2-dimethylsuccinic anhydride or 3,3-dimethylglutaric anhydride or 2,2-dimethylglutaric anhydride)
was added. The reaction vessel was placed in a microwave reactor and the reaction was carried out for
1.5 h at a temperature of 130◦C–160 ◦C at a maximum wave power (300 W). After cooling, the mixture
was diluted with 25 mL of ethyl acetate, and then washed with a 20% hydrochloric acid solution
and with water. The organic layer was dried with anhydrous sodium sulphate and concentrated
until dry in a vacuum evaporator. The crude product was purified by column chromatography (SiO2;
dichloromethane/ethanol ratio: 15:1, v/v) to obtain phosphorus derivatives of 3-carboxyacylbetulinic
acid 12a–c, 13a–c and 14a–c.
3.3. Molecular Docking Study
The 3D structures of studied compounds were generated in their low-energy conformation using
the Gaussian 16 (revision A.03) computer code [49] with the density functional theory (DFT, B3LYP)
and 63–11 + G(d,p) basis sets.
A target macromolecule for molecular docking studies was obtained from the Protein Data
Bank (https://www.rcsb.org/). We used 3D hexameric crystal structure of the CTD-SP1 fragment of
HIV-1 Gag (PDB ID 5I4T). Incomplete or missing side chains of CTD-SP1 protein were restored
with the SWISS-MODEL Workspace (https://swissmodel.expasy.org/) [50]. Geometry optimization
of model was done by the optimization protocol in YASARA Energy Minimization Server (http:
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//www.yasara.org/-minimizationserver.htm) [51] and a ligand-binding site in protein was calculated
using AutoLigand module implicit in AutoDockTools [52].
In this study, AutoDock software version 4.2.6 was employed to perform molecular docking.
AutoDock incorporates limited flexibility in the receptor, and it combines an empirical free-energy force
field with a Lamarckian Genetic Algorithm, providing fast prediction of bound conformations with
predicted free energies of association. The AutoDockTools 1.5.6 software was employed to prepare the
docking procedures. The default spacing of 0.375 Å was adopted for the grid box, and the volume was
set as 60 × 60 × 60 Å. The number of runs was set as 100. The region of interest used for AutoDock
docking was fixed as X = 0.041, Y = 0.010 and Z = 3.855. After calculations, only the 10 highest-scored
poses were returned as a docking result for ligand–cavity configuration. All the obtained results were
ranked according to their score values and presented in kcal/mol. Molecular docking details were
visualized using the BIOVIA Discovery Studio virtual environment [53].
3.4. Molecular Dynamic Simulations
Sybyl-X 2.0/Certara software package running on an HP workstation with a Debian 6.0
operating system was used to perform the majority of the molecular modeling/dynamic simulations
in ligand–protein systems. The RedMD 2.3 program was employed for the macromolecular
simulations [44–46].
4. Conclusions
The 3-carboxyacylbetulinic acid derivatives reported in the paper were formed by attaching a
phosphorus substituent directly to the triterpene system. The diethylphosphate group was introduced
at the C30 position (12a–c), while the diethylphosphonate group at the C29 (13a–c) or C30 position
(14a–c). The compound 14a described in the work shows an in vitro anti-HIV-1 activity with an IC50
value similar to that for the BVM (IC50 values are 0.02 µM and 0.03 µM for 14a and BVM, respectively)
and, at the same time, it has a lower cytotoxicity (CC50 values are 68 µM and 29 µM for 14a and BVM,
respectively). This effect showed that the introduction of the diethylphosphonate group into the C30
position of 3-(3′,3′-dimethylsuccinyl) betulinic acid increases selectivity of this maturation inhibitor.
Analysis of the obtained results shows that among the in vitro tested phosphorus analogues of BVM,
30-dialkylphosphonate derivatives (14a–c) are more active against HIV-1 than 30-dialkylphosphates
(12a–c). Introduction of the phosphonate group at the C29 position (13a–c) provided derivatives with
the lowest activity.
In molecular docking to the CA CTD-SP1 Gag fragment, a molecular target of maturation
inhibitors, an increased number of strong interactions between the ligand 14a and the protein was
observed in comparison to interactions between BVM and the protein. This finding suggests that the
potential molecular mechanism of 14a anti-HIV-1 activity is the same as that of BVM, but is additionally
enhanced by introduction of phosphonate moiety into the C30 position. The comparable RMSD values
are reached at the final step of the MDS, which confirms the relative stability of the ligand–protein
systems for compound 14a.
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Abbreviations
BVM Bevirimat
EC50 Half maximal effective concentration—the concentration of a compound at which 50% of the
Population exhibit a response
TI Therapeutic index
CC50 Cytotoxicity concentration of 50%—concentration required for the reduction of cell viability by 50%
IC50 Half maximal inhibitory concentration—the concentration of a compound required to inhibit 50% of
a specific biological or biochemical function
HSV Herpes simplex virus
HBV Hepatitis B virus
ELISA Enzyme-linked immunosorbent assay
MTT 3-(4,5-Dimethylthiazol-2-yl)-2 5-diphenyltetrazolium bromide
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